ScreenerHero

ATNM Actinium Pharmaceuticals, Inc.

AMEX · US · Healthcare · Biotechnology · actiniumpharma.com
1.070USD-3.60%Mkt Cap: 33.64M $P/E: 2.97

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap33.64M USD
Enterprise Value-232.01K USD
Revenue (TTM)35.09M USD
Gross Profit35.09M USD
Net Income (TTM)-33.89M USD
Revenue/Share1.12 USD
Last Price1.070 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees27
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.97
P/E (Forward)-2.11
PEG—
EV/EBITDA-0.02
EV/Revenue-0.01
P/S0.99
P/B1.15
EPS (TTM)0.36
EPS (Forward)-0.53
52W Range
0.735133% of range1.740
52W High1.740 USD
52W Low0.7351 USD
Profitability
Gross Margin100.00%
Oper. Margin78.76%
EBITDA Margin27.90%
Profit Margin-37652.22%
ROE-432.56%
ROA-65.45%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-24.58M USD
CapEx (TTM)104.00K USD
FCF Margin20.36%
FCF Yield21.23%
Net Debt-35.13M USD
Net Debt/EBITDA-3.59
Balance Sheet
Debt/Equity0.22
Current Ratio4.08
Quick Ratio3.94
Book Value/Sh0.96 USD
Cash/Share1.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateAug 11, 2020
Splits
Last Split1:30
Split DateAug 11, 2020
Analyst Consensus
Rating—
Target (Mean)3.600 USD
Upside (mean)+236.4%
Target Range2.000 USD – 5.000 USD
2.000+236.4% to mean5.000
# Analysts5
Ownership
Shares Out.31.44M
Float31.26M
Insiders8.08%
Institutions17.32%
Short Interest
Short Ratio4.1d
Short % Float2.26%
Short % Out.2.25%
Shares Short707.67K
Short (prev mo.)768.50K
Technical
SMA 501.051 (+1.8%)
SMA 2001.140 (-6.1%)
Beta0.27
S&P 52W Chg16.45%
Avg Vol (30d)160.57K
Avg Vol (10d)81.82K
Technical Indicators
RSI (14)47.2
MACD0.0373
MACD Signal0.0545
MACD Hist.-0.0172
BB Upper1.314 USD
BB Middle1.143 USD
BB Lower0.9722 USD
BB Width29.93%
ATR (14)0.0769 USD
Vol Ratio (20d)0.76x